Drugmaker Teva makes $40B bid for rival Mylan
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva, Mylan, Sandoz and Aurobindo hit with patent suit
Lawmakers to Teva, Mylan: Stop stonewalling our price-fixing probe | Fierce Pharma
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
$40B deal: Teva offers to buy Mylan
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Federal Circuit Upholds Mylan's U.S. Patents on Perforomist® Inhalation Solution; Decision Prevents Approval of Teva ANDA
Mylan, Generic Copaxone Punish Teva (NYSE:TEVA) | Seeking Alpha
Generic Drugmakers Mylan and Teva Face Antitrust Complaint
Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan - The New York Times
Drugmaker Teva makes $40B bid for rival Mylan
Mylan rejects Teva takeover bid as too low | Mint
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
20 States Accuse Generic Drug Companies of Price Fixing - The New York Times
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Teva's Deal for Mylan Shows Corporate Israel's M&A Hunger - WSJ
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
